Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi's Anti-Obesity Drug S-2367 Phase IIb Shows Promising Results

This article was originally published in PharmAsia News

Executive Summary

Shionogi announced May 13 that a Phase IIb analysis of anti-obesity drug S-2367 showed good results in both reduced calorie and low calorie tests. Following the analysis, Shionogi decided to continue the trials and plans to start Phase III trials during the second half of next year. Shionogi considers S-2367, which is being developed in the U.S., as one of its major products to expand overseas. Shionogi plans to obtain approval for the drug in 2011 and market it in 2013. The company is also looking for other companies to jointly develop and market the product. (Click here for more - Japanese language

You may also be interested in...



Shionogi Reports Successful Phase II Results For Obesity Treatment Velneperit; Analysts Lukewarm

TOKYO - Osaka-based antibiotics manufacturer Shionogi reported positive results and "significant reduction in body weight" for its Phase II velneperit trial for obesity, but analysts were lukewarm about the results

ConMed’s Ortho Franchise Prioritizes Pipeline Over External Growth

ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.

Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac

Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.

UsernamePublicRestriction

Register

SC068521

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel